POTTERS BAR, England and
PITTSBURGH, March 12, 2015 /PRNewswire/ -- Mylan N.V.
(NASDAQ: MYL) (the "Parent") and Mylan Inc. ("Mylan" and, together
with the Parent, the "Companies") today announced the successful
completion of the previously announced consent solicitations
relating to Mylan's 3.750% Cash Convertible Notes due 2015, 7.875%
Senior Notes due 2020, 3.125% Senior Notes due 2023, 1.800% Senior
Notes due 2016, 2.600% Senior Notes due 2018, 1.350% Notes due
2016, 2.550% Notes due 2019, 4.200% Notes due 2023 and 5.400% Notes
due 2043 (collectively, the "Notes").
As previously announced on Feb. 27,
2015, the Companies consummated the transactions
contemplated by the Amended and Restated Business Transfer
Agreement and Plan of Merger, dated as of Nov. 4, 2014, between and among Abbott
Laboratories, an Illinois
corporation ("Abbott"), Mylan, the
Parent, and Moon of PA Inc., a Pennsylvania corporation, as a result of which
Mylan became a wholly-owned indirect subsidiary of the Parent and
the Parent acquired Abbott's
non-U.S. developed markets specialty and branded generics business.
In addition, on Feb. 27, 2015, the
Parent fully and unconditionally guaranteed each series of
Notes.
The consent solicitations were made pursuant to the consent
solicitation statement dated March 3,
2015. As of 5:00 p.m.,
New York City time, on
March 11, 2015 (the "Expiration
Date"), the consents were received from holders of a majority in
aggregate principal amount of the outstanding Notes of each series
to the adoption of the amendments described in the consent
solicitation statement. The amendments modify the reporting
covenants primarily to provide that, subject to certain conditions,
the reports, information and other documents required to be filed
with the Securities and Exchange Commission ("SEC") and furnished
to holders of the Notes pursuant to the indentures governing the
Notes may, at the option of Mylan, be filed by and be those of any
direct or indirect parent entity rather than Mylan.
The Companies have caused to be paid to each holder who validly
delivered (and did not validly revoke) a consent prior to the
Expiration Date a consent fee in the amount of $2.50 per $1,000
aggregate principal amount of such holder's Notes. Any questions
regarding these payments should be directed to the Information
Agent and Tabulation Agent, D.F.
King & Co., Inc., attention: Krystal Scrudato, at (800) 398-1247 (toll free)
or (212) 269-5550 (banks and brokers) (collect). J.P. Morgan and
BofA Merrill Lynch acted as Solicitation Agents in connection with
the consent solicitations. After such payment, the Companies and
the trustee under the indentures entered into supplemental
indentures to the indentures governing the Notes to effectuate the
amendments.
The Parent is considered the successor to Mylan, and Mylan is
the Parent's indirect wholly-owned subsidiary. Mylan's address is
1000 Mylan Boulevard, Canonsburg,
Pennsylvania 15317, and its telephone number is (724)
514-1800. The Parent's address is Albany Gate, Darkes Lane, Potters Bar, Herts EN6 1AG, United Kingdom, and the Parent's telephone
number is +44 (0) 1707-853-000.
The Companies regularly post information to www.mylan.com,
including notification of events, news, financial performance,
investor presentations and webcasts, SEC filings and other
information regarding the Companies, their businesses and the
markets they serve.
Forward-Looking Statements
This press release contains
"forward-looking statements." These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements may include,
without limitation, statements about the acquisition (the
"Transaction") by the Parent of the non-U.S. developed markets
specialty and branded generics business (the "Business") of both
Mylan and Abbott, benefits and
synergies of the Transaction, future opportunities for the
Companies and products, and any other statements regarding Mylan's
or the Parent's statements about future opportunities for the
Companies and products and any other statements regarding the
Companies' future operations, anticipated business levels, future
earnings, planned activities, anticipated growth, market
opportunities, strategies, competition and other expectations and
targets for future periods. These often may be identified by the
use of words such as "will," "may," "could," "should," "would,"
"project," "believe," "anticipate," "expect," "plan," "estimate,"
"forecast," "potential," "intend," "continue," "target" and
variations of these words or comparable words. Because
forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: the ability to meet expectations regarding
the accounting and tax treatments of the Transaction; changes in
relevant tax and other laws, including but not limited to changes
in healthcare and pharmaceutical laws and regulations in the U.S.
and abroad; the integration of the Business being more difficult,
time-consuming, or costly than expected; operating costs, customer
loss and business disruption (including, without limitation,
difficulties in maintaining relationships with employees,
customers, clients, or suppliers) being greater than expected
following the Transaction; the retention of certain key employees
of the Business being difficult; the possibility that Mylan and the
Parent may be unable to achieve expected synergies and operating
efficiencies in connection with the Transaction within the expected
time-frames or at all and to successfully integrate the Business;
expected or targeted future financial and operating performance and
results; the capacity to bring new products to market, including
but not limited to where the Companies use their business judgment
and decide to manufacture, market, and/or sell products, directly
or through third parties, notwithstanding the fact that allegations
of patent infringement(s) have not been finally resolved by the
courts (i.e., an "at-risk launch"); success of clinical trials and
the Companies' ability to execute on new product opportunities; the
scope, timing, and outcome of any ongoing legal proceedings and the
impact of any such proceedings on financial condition, results of
operations and/or cash flows; the ability to protect intellectual
property and preserve intellectual property rights; the effect of
any changes in customer and supplier relationships and customer
purchasing patterns; the ability to attract and retain key
personnel; changes in third-party relationships; the impacts of
competition; changes in the economic and financial conditions of
the Companies' business; the inherent challenges, risks, and costs
in identifying, acquiring, and integrating complementary or
strategic acquisitions of other companies, products or assets and
in achieving anticipated synergies; uncertainties and matters
beyond the control of management; inherent uncertainties involved
in the estimates and judgments used in the preparation of financial
statements, and the providing of estimates of financial measures,
in accordance with accounting principles generally accepted in
the United States of America and
related standards or on an adjusted basis; and the other risks
detailed in the Companies' filings with the SEC. You can access the
Companies' respective filings, including the Parent's prospectus
filed with the SEC on December 24,
2014, through the SEC's website at www.sec.gov, and the
Companies strongly encourage you to do so. The Companies undertake
no obligation to update any statements herein for revisions or
changes after the date of this press release.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of around 1,400 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral
therapies, upon which approximately 40% of HIV/AIDS patients in
developing countries depend. We also operate one of the largest
active pharmaceutical ingredient manufacturers and currently market
products in about 145 countries and territories. Our workforce of
approximately 30,000 people is dedicated to creating better health
for a better world, one person at a time. Learn more at
mylan.com.
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-nv-and-mylan-inc-announce-successful-completion-of-consent-solicitations-for-mylan-incs-notes-300049761.html
SOURCE Mylan N.V.